Comparing two CBD formulations for better absorption in healthy adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the relative bioavailability of a new fast-dissolving cheek-administered cannabidiol strip compared to traditional cannabidiol powder in healthy male adults. By assessing how well each formulation is absorbed into the body, the research seeks to inform future dosing regimens for NFL athletes, particularly in the context of concussion management. Participants will be monitored for pharmacokinetics over a 13-hour period following administration. The findings will help optimize CBD formulations for therapeutic use in sports medicine.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18 - 35 years old
2. Clinical labs within the stated normal range of the Royal University Hospital Test Centre, or values outside the stated normal range that are not of clinical significance as determined by the qualified investigator.
3. No clinically significant disease on medical history or clinically significant findings on physical examination including vital signs as determined by the qualified investigator.
4. Ability to stay in the clinic trial unit for 13 hours on the day of each single oral dose.
5. Ability to return for blood draws in the subsequent days.

Exclusion Criteria:

1. History or presence of significant gastrointestinal, liver or kidney disease or any other condition known to interfere with drug pharmacokinetics including bioavailability or increase risk of adverse effects.
2. History or presence of serious cardiovascular disease, such as ischaemic heart disease, arrhythmias, poorly controlled hypertension or severe heart failure
3. Males whose partners are trying to conceive (i.e. male subjects intending to start a family during the study period)
4. Lack of medically acceptable contraception by participants whose female partners have childbearing potential for the duration of the study.
5. Personal or family history of schizophrenia or any other psychotic disorder
6. Current or past drug or alcohol dependence or abuse
7. Use of Cannabis-based therapy within 2 months (Participants who have previously used a Cannabis-based therapy may be included if they have a 2-month period without use of Cannabis-based therapy prior to enrolment in the study)
8. Use of recreational Cannabis within 2 months (Participants who have previously used recreational Cannabis may be included if they have a 2-month period without use of recreational Cannabis prior to enrolment in the study)
9. Use of psychotropic medications with serotonergic activity (e.g. Selective Serotonin Reuptake Inhibitors, Tricyclic Antidepressants, Atypical Neuroleptics) within one week
10. Use of narcotic medications (e.g. Codeine, Morphine, Oxycontin) within one week
11. Use of any other medication known to interact with medicinal Cannabis within one week.
12. Allergy or known intolerance to any of the compounds within the study preparation.
13. Resting heart rate HR \< 50 bpm or \> 100 bpm or seated blood pressure \< 100/60 or higher than 140/90
14. Inability of study participants to attend and complete all study visits
15. Bleeding disorder
16. Known low hematocrit

Where it's running

• University of Saskatchewan
  Saskatoon, Saskatchewan, Canada Recruiting

Study contacts

• Principal investigator: Payam Dehghani, MD — Pasqua Hospital
• Study coordinator: Abdul Salama, PharmD
• Email: abs915@usask.ca
• Phone: 3065600094

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Levetiracetam Dosing in Critically Ill on CRRT

  This study tests how levetiracetam behaves in the bodies of adults on continuous renal replacement therapy to help figure out the best dosing.

  Recruiting Chulalongkorn University · Pathum Wan, Bangkok · NCT07918833

• Trigonelline Monohydrate for NAD+ Metabolism in Healthy Adults

  A small study in healthy adults tests whether taking trigonelline monohydrate by mouth for 4 weeks can change NAD+ levels and how the body handles the supplement, compared with NMN and placebo.

  Recruiting Phase 1 dsm-firmenich Switzerland AG · Guelph, Ontario - on · NCT07880925

• Cetuximab bioequivalence test in healthy men

  This study tests whether a cetuximab injection is bioequivalent to Erbitux in healthy men to see if they behave the same in the body.

  Recruiting Phase 1 HC Biopharma Inc. · Haikou, Hainan · NCT07813468

• GenSci142 as a vaginal treatment for bacterial vaginosis

  This study tests whether GenSci142 given as vaginal doses is safe and may help BV patients aged 18–50 compared with clindamycin cream.

  Recruiting at 9 sites Phase 1 Changchun GeneScience Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality and 8 other locations · NCT07663838

• Food's effect on how DW-1021 (pelubiprofen 45 mg + tramadol 45.9 mg) is absorbed in healthy adults

  This study will test whether eating a high-fat meal changes how DW-1021 (pelubiprofen plus tramadol) is absorbed in healthy adult men.

  Recruiting at 2 sites Phase 1 Haiphong University of Medicine and Pharmacy · Haiphong, Hai Phong and 1 other locations · NCT07060209

• High-potency cannabis effects immediately and after a short break

  This test will try smoked cannabis at about 50 mg and 100 mg THC versus placebo in adults who smoke cannabis nearly every day to see how it affects them right away and after a short period without use.

  Recruiting Phase 1 University of California, Los Angeles · Los Angeles, California · NCT06859723

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.